الفهرس 
Blood LipidsOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
Lipid abnormalities are well known characteristics of NS with multiple ■mechanisms being involved in its origin. It may aggravate glomerulosclerosis, land enhance the progression of glomerular disease (O Lbricht et al., 1999). Jhe available data do not provide a conclusive answers to the question ■ of whether or not a lipid lowering therapy ameliorate the progression of glomerular diseases. The present study comprised 43 patients with persistent nephrotic syndrome and hypercholesterolemia, who were randomized into two groups, evaluated and followed up for 12 months to assess the effect of treatment of nephrotic induced dyslipidemia on the progression of kidney lesion and the possible side effects of such drug used. The present study showed: 1- Highly significant reduction (30-40%) in serum levels of cholesterol and LDL-in fluvastatin group after 6 months treatment (P<0.01) compared to control group, but on comparison to basal values there was highly significant reduction after 3 months (P< 0.01). 2- No significant difference between both groups regarding HDL levels along 1 year (P> 0.05). 3- The degree of proteinuria decreased after 6 months of fluvastatin treatment compared to control group, and such reduction became significant at 1 year (48%) (P< 0.05). 4- Highly significant elevation in .serum albumin (30%) was observed in fluvastatin group after 6 months and thereafter, compared to basal values (P< 0.01), and when compared to control group the relation was significant (P< 0.05). Lipid abnormalities are well known characteristics of NS with multiple ■mechanisms being involved in its origin. It may aggravate glomerulosclerosis, land enhance the progression of glomerular disease (O Lbricht et al., 1999). Jhe available data do not provide a conclusive answers to the question ■ of whether or not a lipid lowering therapy ameliorate the progression of glomerular diseases. The present study comprised 43 patients with persistent nephrotic syndrome and hypercholesterolemia, who were randomized into two groups, evaluated and followed up for 12 months to assess the effect of treatment of nephrotic induced dyslipidemia on the progression of kidney lesion and the possible side effects of such drug used. The present study showed: 1- Highly significant reduction (30-40%) in serum levels of cholesterol and LDL-in fluvastatin group after 6 months treatment (P<0.01) compared to control group, but on comparison to basal values there was highly significant reduction after 3 months (P< 0.01). 2- No significant difference between both groups regarding HDL levels along 1 year (P> 0.05). 3- The degree of proteinuria decreased after 6 months of fluvastatin treatment compared to control group, and such reduction became significant at 1 year (48%) (P< 0.05). 4- Highly significant elevation in .serum albumin (30%) was observed in fluvastatin group after 6 months and thereafter, compared to basal values (P< 0.01), and when compared to control group the relation was significant (P< 0.05). Lipid abnormalities are well known characteristics of NS with multiple ■mechanisms being involved in its origin. It may aggravate glomerulosclerosis, land enhance the progression of glomerular disease (O Lbricht et al., 1999). Jhe available data do not provide a conclusive answers to the question ■ of whether or not a lipid lowering therapy ameliorate the progression of glomerular diseases. The present study comprised 43 patients with persistent nephrotic syndrome and hypercholesterolemia, who were randomized into two groups, evaluated and followed up for 12 months to assess the effect of treatment of nephrotic induced dyslipidemia on the progression of kidney lesion and the possible side effects of such drug used. The present study showed: 1- Highly significant reduction (30-40%) in serum levels of cholesterol and LDL-in fluvastatin group after 6 months treatment (P<0.01) compared to control group, but on comparison to basal values there was highly significant reduction after 3 months (P< 0.01). 2- No significant difference between both groups regarding HDL levels along 1 year (P> 0.05). 3- The degree of proteinuria decreased after 6 months of fluvastatin treatment compared to control group, and such reduction became significant at 1 year (48%) (P< 0.05). 4- Highly significant elevation in .serum albumin (30%) was observed in fluvastatin group after 6 months and thereafter, compared to basal values (P< 0.01), and when compared to control group the relation was significant (P< 0.05). p- Fluvastatin is safe in long term use in nephrotic patients regarding liver I functions and muscle enzymes, however, EMG evaluation and follow up of proximal muscles should be performed in cases who are planned to receive it. p- The number of cases with moderate to severe degree of fat deposits in the renal tissue, was higher in fluvastatin group compared to control group and such* difference was highly significant (P= 0.003) but after 1 year of fluvastatin treatment, the difference became insignificant. from our study we can conclude that: f- Control of nephrotic dyslipidemia is associated with persistent clinical remission and partial laboratory remission after one year, moreover, it is associated with significant mobilization of fat deposits from renal tissue after one year of treatment. |2- Fluvastatin is a safe statin not associated with clinical evidence of myopathy or elevated liver enzymes on long term use in nephrotics. However, we recommend EMG evaluation and follow up for proximal muscles of patients who are planned to receive statins. jj- Thus, one can conclude that treatment of nephrotic dyslipidemia with fluvastatin can retard the progression of the disease and it should be considered in the treatment stratigies of such patients.